Table 1.
| Characteristics | Lenzilumab group |
Control group |
P |
|---|---|---|---|
| (n=12) | (n=27) | ||
| Age (range), years | 65 (52-70) | 68 (61-76) | .25 |
| Male | 8 (66.7) | 19 (70.4) | >.99 |
| Female | 4 (33.3) | 8 (29.6) | >.99 |
| Race | |||
| White | 9 (75.0) | 17 (63.0) | .79 |
| Asian | 2 (16.7) | 5 (18.5) | >.99 |
| American Indian/Native American | 1 (8.3) | 0 (0.0) | .36 |
| Comorbidities | |||
| Diabetes mellitus | 7 (58.3) | 14 (51.9) | >.99 |
| Hypertension | 7 (58.3) | na | na |
| Obesity (BMI > 30 kg/m2) | 6 (50.0) | 9 (33.3) | .54 |
| Coronary artery disease | 2 (16.7) | 4 (15) | >.99 |
| Kidney transplantation | 1 (8.3) | na | na |
| Obstructive lung disease | 4 (33.3) | na | na |
| Chronic obstructive pulmonary disease | 2 (16.7) | 11 (40.7) | .47 |
| Reactive airway disease | 1 (8.3) | na | na |
| Temperature, °C | 38 (37.25-38.5) | 37.5 (37.1-38.4) | .76 |
| Inflammatory markers before treatment | |||
| CRP (≤8.0 mg/mL) | 103.2 (52.7-159.9) | 74.4 (42.2-131.5) | .25 |
| Ferritin (24-336 μg/L) | 596.0 (358.3-709.0) | 673.0 (406.8-1012.8) | .75 |
| IL-6 (≤1.8 pg/mL) | 30.95 (24.18-34.05) | 29.20 (13.55-40.70) | .87 |
| D-dimer (≤500 ng/mL) | 829 (513.5-1298.5) | 916.0 (585.0-1299.0) | .84 |
| Lymphocyte count before treatment (0.95-3.07×109/L) | 0.75 (0.55-1.04) | 0.76 (0.59-1.01) | .91 |
| Oxygen therapy before treatment | |||
| Nasal cannula (=4 clinical ordinal endpoint scale) | 8 (66.7) | 20 (74.0) | >.99 |
| High-flow oxygen/NIPPV (=3 clinical ordinal endpoint scale) | 4 (33.3) | 7 (25.9) | .73 |
| Invasive ventilation (=2 clinical ordinal endpoint scale) | 0 (0.0) | 0 (0.0) | >.99 |
| SpO2/Fio2 before treatment | 280.9 (252.5-317.9) | 289.1 (254.9-342.0) | .98 |
a
BMI = body mass index; CRP = C-reactive protein; Fio2 = fraction of inspired oxygen; IL = interleukin; na = not available; NIPPV = noninvasive positive pressure ventilation; SpO2 = oxygen saturation.
b
Values shown are n (%) unless otherwise specified.